AMEDICA Corp Form 8-K February 27, 2017

**UNITED STATES** 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d) of the

**Securities Exchange Act of 1934** 

Date of report (Date of earliest event reported): February 27, 2017

**Amedica Corporation** 

(Exact name of registrant as specified in its charter)

**Delaware** 001-33624 84-1375299 (State or other jurisdiction (Commission (IRS Employer

of incorporation) File Number) Identification No.)

1885 West 2100 South

84119

Salt Lake City, UT

24ga / 1111/1917 1011/1917 1011/1917
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 839-3500
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item	8 01	Other	Events.

On February 27, 2017, Amedica Corporation issued a press release announcing results of independent femoral head wear testing. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Amedica Corporation Press Release dated February 27, 2017.

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## AMEDICA CORPORATION

Date: February 27, 2017 /s/ B. Sonny Bal
B. Sonny Bal, MD
Chief Executive Officer